Enzymotec Ltd. (NASDAQ:ENZY) issued an update on its FY16 earnings guidance on Wednesday morning. The company provided EPS guidance of $0.17-0.19 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.27. The company issued revenue guidance of $47.5-49.5 million, compared to the consensus revenue estimate of $52.99 million.

Shares of Enzymotec Ltd. (NASDAQ:ENZY) opened at 5.70 on Friday. The stock has a market capitalization of $129.50 million, a price-to-earnings ratio of 30.00 and a beta of 1.26. Enzymotec Ltd. has a 52 week low of $5.20 and a 52 week high of $10.32. The firm’s 50-day moving average is $6.83 and its 200-day moving average is $7.77.

Enzymotec (NASDAQ:ENZY) last posted its quarterly earnings data on Wednesday, November 16th. The company reported $0.03 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by $0.04. Enzymotec had a return on equity of 3.12% and a net margin of 8.37%. The company had revenue of $11.40 million for the quarter, compared to analyst estimates of $13.29 million. During the same quarter in the previous year, the firm posted $0.08 earnings per share. The company’s quarterly revenue was down 8.1% on a year-over-year basis. Analysts forecast that Enzymotec Ltd. will post $0.27 earnings per share for the current fiscal year.

Several equities research analysts have recently commented on ENZY shares. Zacks Investment Research downgraded shares of Enzymotec from a buy rating to a hold rating in a research note on Friday, July 22nd. Jefferies Group reiterated a hold rating on shares of Enzymotec in a research note on Thursday, August 4th. Finally, Wells Fargo & Co. downgraded shares of Enzymotec from an outperform rating to a market perform rating in a research note on Thursday.

Hedge funds and other institutional investors have recently modified their holdings of the company. Menta Capital LLC boosted its position in shares of Enzymotec by 12.4% in the second quarter. Menta Capital LLC now owns 48,488 shares of the company’s stock valued at $405,000 after buying an additional 5,362 shares during the period. Janus Capital Management LLC boosted its position in shares of Enzymotec by 79.3% in the second quarter. Janus Capital Management LLC now owns 248,485 shares of the company’s stock valued at $2,077,000 after buying an additional 109,933 shares during the period. Van ECK Associates Corp boosted its position in shares of Enzymotec by 5.9% in the second quarter. Van ECK Associates Corp now owns 12,659 shares of the company’s stock valued at $106,000 after buying an additional 706 shares during the period. Laurion Capital Management LP acquired a new position in shares of Enzymotec during the second quarter valued at about $1,572,000. Finally, Algert Global LLC boosted its position in shares of Enzymotec by 81.3% in the second quarter. Algert Global LLC now owns 38,046 shares of the company’s stock valued at $318,000 after buying an additional 17,058 shares during the period. 36.19% of the stock is owned by hedge funds and other institutional investors.

Enzymotec Company Profile

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

5 Day Chart for NASDAQ:ENZY

Receive News & Stock Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related stocks with our FREE daily email newsletter.